EA201990413A1 - Способ лечения печеночной энцефалопатии - Google Patents
Способ лечения печеночной энцефалопатииInfo
- Publication number
- EA201990413A1 EA201990413A1 EA201990413A EA201990413A EA201990413A1 EA 201990413 A1 EA201990413 A1 EA 201990413A1 EA 201990413 A EA201990413 A EA 201990413A EA 201990413 A EA201990413 A EA 201990413A EA 201990413 A1 EA201990413 A1 EA 201990413A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hepatic encephalopathy
- treating hepatic
- treating
- encephalopathy
- biotin
- Prior art date
Links
- 208000007386 hepatic encephalopathy Diseases 0.000 title abstract 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 2
- 229960002685 biotin Drugs 0.000 abstract 1
- 235000020958 biotin Nutrition 0.000 abstract 1
- 239000011616 biotin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305989.2A EP3275439A1 (en) | 2016-07-29 | 2016-07-29 | Method for treating hepatic encephalopathy |
PCT/EP2017/069194 WO2018020010A1 (en) | 2016-07-29 | 2017-07-28 | Method for treating hepatic encephalopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201990413A1 true EA201990413A1 (ru) | 2019-06-28 |
Family
ID=56618106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990413A EA201990413A1 (ru) | 2016-07-29 | 2017-07-28 | Способ лечения печеночной энцефалопатии |
Country Status (23)
Country | Link |
---|---|
US (2) | US10117854B2 (da) |
EP (2) | EP3275439A1 (da) |
JP (1) | JP2019522030A (da) |
KR (1) | KR20190034550A (da) |
AU (1) | AU2017303346A1 (da) |
BR (1) | BR112019001178A2 (da) |
CA (1) | CA3031302A1 (da) |
CY (1) | CY1122348T1 (da) |
DK (1) | DK3319601T3 (da) |
EA (1) | EA201990413A1 (da) |
ES (1) | ES2751154T3 (da) |
HK (1) | HK1254833B (da) |
HR (1) | HRP20191798T1 (da) |
HU (1) | HUE046590T2 (da) |
IL (1) | IL264460B (da) |
LT (1) | LT3319601T (da) |
MA (1) | MA42419B1 (da) |
ME (1) | ME03520B (da) |
PL (1) | PL3319601T3 (da) |
PT (1) | PT3319601T (da) |
RS (1) | RS59300B1 (da) |
SI (1) | SI3319601T1 (da) |
WO (1) | WO2018020010A1 (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
MX2018004788A (es) * | 2018-04-18 | 2019-10-21 | Alparis Sa De Cv | Nuevas fases solidas de rifaximina. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0788304B2 (ja) * | 1988-03-05 | 1995-09-27 | 三生製薬株式会社 | 高アンモニア血症治療剤 |
US5814650A (en) * | 1992-09-28 | 1998-09-29 | Lifegroup S.P.A. | Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions |
DE20202562U1 (de) * | 2002-02-19 | 2002-05-23 | Orthomol Pharmazeutische Vertr | Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika |
US20040219188A1 (en) * | 2003-05-02 | 2004-11-04 | Comer Gail M. | Composition and methods for nutritional management of patients with hepatic disease |
US20130004545A1 (en) | 2009-12-23 | 2013-01-03 | Lupin Limited | Slow release pharmaceutical compositions of iloperidone |
FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
FR2958166B1 (fr) * | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
WO2014177286A1 (en) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
CN105614851A (zh) * | 2015-12-27 | 2016-06-01 | 劲膳美生物科技股份有限公司 | 肝性脑病医学配方食品 |
EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
-
2016
- 2016-07-29 EP EP16305989.2A patent/EP3275439A1/en not_active Ceased
-
2017
- 2017-07-28 EP EP17742782.0A patent/EP3319601B1/en active Active
- 2017-07-28 KR KR1020197002991A patent/KR20190034550A/ko not_active Application Discontinuation
- 2017-07-28 AU AU2017303346A patent/AU2017303346A1/en not_active Abandoned
- 2017-07-28 ME MEP-2019-267A patent/ME03520B/me unknown
- 2017-07-28 MA MA42419A patent/MA42419B1/fr unknown
- 2017-07-28 WO PCT/EP2017/069194 patent/WO2018020010A1/en active Application Filing
- 2017-07-28 LT LT17742782T patent/LT3319601T/lt unknown
- 2017-07-28 JP JP2019504740A patent/JP2019522030A/ja not_active Ceased
- 2017-07-28 PT PT17742782T patent/PT3319601T/pt unknown
- 2017-07-28 EA EA201990413A patent/EA201990413A1/ru unknown
- 2017-07-28 ES ES17742782T patent/ES2751154T3/es active Active
- 2017-07-28 PL PL17742782T patent/PL3319601T3/pl unknown
- 2017-07-28 CA CA3031302A patent/CA3031302A1/en not_active Abandoned
- 2017-07-28 BR BR112019001178-1A patent/BR112019001178A2/pt not_active IP Right Cessation
- 2017-07-28 RS RSP20191218 patent/RS59300B1/sr unknown
- 2017-07-28 HU HUE17742782A patent/HUE046590T2/hu unknown
- 2017-07-28 SI SI201730093T patent/SI3319601T1/sl unknown
- 2017-07-28 DK DK17742782T patent/DK3319601T3/da active
-
2018
- 2018-03-26 US US15/935,695 patent/US10117854B2/en not_active Expired - Fee Related
- 2018-09-18 US US16/134,144 patent/US10328059B2/en not_active Expired - Fee Related
- 2018-10-31 HK HK18113925.3A patent/HK1254833B/zh not_active IP Right Cessation
-
2019
- 2019-01-24 IL IL264460A patent/IL264460B/en active IP Right Grant
- 2019-10-03 HR HRP20191798TT patent/HRP20191798T1/hr unknown
- 2019-11-18 CY CY20191101208T patent/CY1122348T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL264460A (en) | 2019-02-28 |
IL264460B (en) | 2021-06-30 |
HK1254833B (zh) | 2020-05-22 |
ME03520B (me) | 2020-04-20 |
LT3319601T (lt) | 2019-11-11 |
US10328059B2 (en) | 2019-06-25 |
PT3319601T (pt) | 2019-09-18 |
US20190070150A1 (en) | 2019-03-07 |
KR20190034550A (ko) | 2019-04-02 |
EP3319601B1 (en) | 2019-08-28 |
HUE046590T2 (hu) | 2020-03-30 |
MA42419B1 (fr) | 2019-11-29 |
WO2018020010A1 (en) | 2018-02-01 |
CA3031302A1 (en) | 2018-02-01 |
BR112019001178A2 (pt) | 2019-04-30 |
ES2751154T3 (es) | 2020-03-30 |
US10117854B2 (en) | 2018-11-06 |
EP3275439A1 (en) | 2018-01-31 |
RS59300B1 (sr) | 2019-10-31 |
AU2017303346A1 (en) | 2019-01-31 |
DK3319601T3 (da) | 2019-11-18 |
HRP20191798T1 (hr) | 2019-12-27 |
SI3319601T1 (sl) | 2019-11-29 |
EP3319601A1 (en) | 2018-05-16 |
PL3319601T3 (pl) | 2020-06-29 |
MA42419A (fr) | 2018-05-16 |
JP2019522030A (ja) | 2019-08-08 |
CY1122348T1 (el) | 2021-01-27 |
US20180214417A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124368T1 (el) | Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman | |
CL2016002144A1 (es) | Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos. | |
MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
CL2017002781A1 (es) | Métodos de tratamiento de enfermedad de alzheimer | |
TW201713333A (en) | Methods of treating a neurodegenerative disease | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
EA201791110A1 (ru) | Сублингвальное введение рилузола | |
MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
BR112017000730A2 (pt) | derivados de pirrolidinona como inibidores de metap-2 | |
DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
TR201901687T4 (tr) | Hepatik ensefalopati tedavisinde kullanıma yönelik steroid bileşik. | |
MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
EP3702470A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
CY1122348T1 (el) | Μεθοδος για την θεραπευτικη αντιμετωπιση της ηπατικης εγκεφαλοπαθειας | |
PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
MY178971A (en) | Triaminopyrimidine compounds useful for preventing or treating malaria | |
PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
CL2020000586A1 (es) | Moduladores de la expresión de enac. | |
MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
MX2016008968A (es) | Compuestos organicos. | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
MX2018004532A (es) | Combinacion de trazodona y gabapentina para el tratamiento de dolor. | |
NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
MX2018012193A (es) | Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus. |